News - News - MicroPort® CardioFlow

News

Always Share with You
Every Bit of Our Progress

News

2023.10.28

VitaFlow Liberty^® by MicroPort^® CardioFlow Successfully Completed Five Pre-Market Implants in Denmark

Read More
2023.10.13

MicroPort^® CardioFlow Receives Approval for VitaFlow Liberty^® in Russia

Read More
2023.09.18

MicroPort^® CardioFlow Receives Approval for Alwide^® Plus in Russia

Shanghai, China — Recently, MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) has received marketing approval for its second-generation balloon catheter , Alwide® Plus Balloon Catheter (hereinafter referred to as "Alwide® Plus") from Russian State Food and Drug Administration(RZN).

Read More
2023.09.08

A New Chapter is Beginning—MicroPort^® CardioFlow’s VitaFlow Liberty^® Completes First Implantation in Thailand

On September 4, 2023, at 15:00 local time, the VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty®"), self-developed by MicroPort® CardioFlow, VitaFlow Liberty® was presented at the Police General Hospital in Thailand. Under the leadership of Prof. Luo Jianfang from Guangdong Provincial People's Hospital, Prof. Anuruck Jeamanukoolkit, an expert from the hospital, together with his team, successfully performed the first implantation of VitaFlow Liberty® in Thailand. Postoperative imaging showed that the patient's valve was in good shape and position, with no perivalvular leakage or coronary occlusion, and the surgery was a complete success.

Read More
2023.08.06

International Exchange: MicroPort^® CardioFlow and Thai Expert Team Visited Xiamen Cardiovascular Hospital Xiamen University to Observe the Implantation Surgery of VitaFlow Liberty^®

Shanghai, China - As a new generation of TAVI product developed by MicroPort® CardioFlow Medtech Corpration, VitaFlow Liberty® is the first and only motorized retrievable transcatheter aortic valve system in the world. Recently, MicroPort® CardioFlow team accompanied the expert team from four renowned hospitals in Thailand to Xiamen Cardiovascular Hospital Xiamen University to observe the successful implantation of a patient with moderate aortic stenosis combined with severe regurgitation by the local physician team using the product, which has been reprinted and reported by a number of media outlets.

Read More

<6 7 8 9 10 11 12 13 14 15 16 >

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

TOP

互联网药品信息服务资格证书编号：（沪）-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.